CD37 and neoplasm: As a way to overcome the issue of CD19 loss, a bispecific CD37/CD19-CAR has been proposed, and showed potent cytotoxicity against CD37-positive lymphoma cells in vitro, decreased tumor burden, and improved survival rate in a Raji-xenograft tumor NSG mice model [117].